Apellis Pharmaceuticals Announced SYFOVRE Reduced Nonsubfoveal GA Lesion Growth By Up To 45% Between Months 24-30 Compared To Projected Sham In The GALE Long-term Extension Study
Portfolio Pulse from Charles Gross
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced data from the GALE extension study showing that SYFOVRE, the first and only FDA approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), reduced GA lesion growth by up to 45% in patients with nonsubfoveal lesions after 30 months of continuous treatment.
July 30, 2023 | 6:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals' SYFOVRE has shown significant efficacy in reducing GA lesion growth in a long-term study, reinforcing its position as a leading treatment for AMD.
The positive results from the GALE extension study not only reinforce the efficacy and safety of SYFOVRE but also strengthen Apellis' position in the market for AMD treatments. This could potentially lead to increased demand for SYFOVRE, positively impacting Apellis' revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100